CN1694701A - 治疗包括成瘾与抑郁症在内的与mGLU受体相关疾病的mGLU受体拮抗剂 - Google Patents

治疗包括成瘾与抑郁症在内的与mGLU受体相关疾病的mGLU受体拮抗剂 Download PDF

Info

Publication number
CN1694701A
CN1694701A CNA038250217A CN03825021A CN1694701A CN 1694701 A CN1694701 A CN 1694701A CN A038250217 A CNA038250217 A CN A038250217A CN 03825021 A CN03825021 A CN 03825021A CN 1694701 A CN1694701 A CN 1694701A
Authority
CN
China
Prior art keywords
nicotine
administration
rats
metabotropic glutamate
mpep
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CNA038250217A
Other languages
English (en)
Chinese (zh)
Inventor
A·马尔库
P·肯尼
N·佩特森
S·塞梅诺娃
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Novartis AG
Scripps Research Institute
Original Assignee
Novartis AG
Scripps Research Institute
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis AG, Scripps Research Institute filed Critical Novartis AG
Publication of CN1694701A publication Critical patent/CN1694701A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/32—Alcohol-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/34—Tobacco-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/36—Opioid-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Addiction (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurosurgery (AREA)
  • Psychiatry (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Epidemiology (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pyridine Compounds (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
CNA038250217A 2002-09-10 2003-09-10 治疗包括成瘾与抑郁症在内的与mGLU受体相关疾病的mGLU受体拮抗剂 Pending CN1694701A (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US40986702P 2002-09-10 2002-09-10
US60/409,867 2002-09-10

Related Child Applications (1)

Application Number Title Priority Date Filing Date
CN2012102160928A Division CN102793698A (zh) 2002-09-10 2003-09-10 治疗包括成瘾与抑郁症在内的与mGLU受体相关疾病的mGLU受体拮抗剂

Publications (1)

Publication Number Publication Date
CN1694701A true CN1694701A (zh) 2005-11-09

Family

ID=31994019

Family Applications (2)

Application Number Title Priority Date Filing Date
CNA038250217A Pending CN1694701A (zh) 2002-09-10 2003-09-10 治疗包括成瘾与抑郁症在内的与mGLU受体相关疾病的mGLU受体拮抗剂
CN2012102160928A Pending CN102793698A (zh) 2002-09-10 2003-09-10 治疗包括成瘾与抑郁症在内的与mGLU受体相关疾病的mGLU受体拮抗剂

Family Applications After (1)

Application Number Title Priority Date Filing Date
CN2012102160928A Pending CN102793698A (zh) 2002-09-10 2003-09-10 治疗包括成瘾与抑郁症在内的与mGLU受体相关疾病的mGLU受体拮抗剂

Country Status (10)

Country Link
US (2) US8354447B2 (https=)
EP (1) EP1539149B1 (https=)
JP (3) JP2006501265A (https=)
CN (2) CN1694701A (https=)
AT (1) ATE539768T1 (https=)
AU (1) AU2003270166A1 (https=)
BR (1) BR0314192A (https=)
CA (1) CA2498022C (https=)
ES (1) ES2381664T3 (https=)
WO (1) WO2004024150A2 (https=)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN110151184A (zh) * 2019-04-19 2019-08-23 昆明依利科特科技有限公司 非接触式吸毒人员快速检测系统及方法

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE521512C2 (sv) 2001-06-25 2003-11-11 Niconovum Ab Anordning för administrering av en substans till främre delen av en individs munhåla
PT1578422E (pt) 2002-12-20 2007-06-14 Niconovum Ab Material particulado contendo nicotina fisicamente e quimicamente estável
AR059898A1 (es) 2006-03-15 2008-05-07 Janssen Pharmaceutica Nv Derivados de 3-ciano-piridona 1,4-disustituida y su uso como moduladores alostericos de los receptores mglur2
AU2007224584A1 (en) 2006-03-16 2007-09-20 Niconovum Ab Improved snuff composition
TW200845978A (en) 2007-03-07 2008-12-01 Janssen Pharmaceutica Nv 3-cyano-4-(4-tetrahydropyran-phenyl)-pyridin-2-one derivatives
TW200900065A (en) 2007-03-07 2009-01-01 Janssen Pharmaceutica Nv 3-cyano-4-(4-pyridinyloxy-phenyl)-pyridin-2-one derivatives
CN101801930B (zh) 2007-09-14 2013-01-30 奥梅-杨森制药有限公司 1,3-二取代的-4-苯基-1h-吡啶-2-酮
PL2200985T3 (pl) 2007-09-14 2011-12-30 Ortho Mcneil Janssen Pharmaceuticals Inc 1,3-Dipodstawione-4-(arylo-X-fenylo)-1H-pirydyn-2-ony
SI2203439T1 (sl) 2007-09-14 2011-05-31 Ortho Mcneil Janssen Pharm 1',3'-disubstituirani 4-fenil-3,4,5,6-tetrahidro-2H-1'H-(1,4')bipiridinil-2'-oni
CN101861316B (zh) 2007-11-14 2013-08-21 奥梅-杨森制药有限公司 咪唑并[1,2-a]吡啶衍生物及其作为MGLUR2受体的正变构调节剂的用途
EP2344470B1 (en) 2008-09-02 2013-11-06 Janssen Pharmaceuticals, Inc. 3-azabicyclo[3.1.0]hexyl derivatives as modulators of metabotropic glutamate receptors
WO2010043396A1 (en) 2008-10-16 2010-04-22 Ortho-Mcneil-Janssen Pharmaceuticals, Inc. Indole and benzomorpholine derivatives as modulators of metabotropic glutamate receptors
JP5690277B2 (ja) 2008-11-28 2015-03-25 ジャンセン ファーマシューティカルズ， インコーポレイテッド． 代謝型グルタミン酸受容体の調節因子としてのインドールおよびベンゾオキサジン誘導体
BRPI1010831A2 (pt) 2009-05-12 2016-04-05 Addex Pharmaceuticals Sa derivados de 1,2,4-triazolo[4,3-a]piridina e seu como moduladores alostéricos positivos de receptores de mglur2
MY153913A (en) 2009-05-12 2015-04-15 Janssen Pharmaceuticals Inc 7-aryl-1,2,4-triazolo[4,3-a]pyridine derivatives and their use as positive allosteric modulators of mglur2 receptors
CN102439008B (zh) 2009-05-12 2015-04-29 杨森制药有限公司 1,2,4-三唑并[4,3-a]吡啶衍生物及其用于治疗或预防神经和精神病症的用途
AU2011328203B2 (en) 2010-11-08 2015-03-19 Janssen Pharmaceuticals, Inc. 1,2,4-triazolo[4,3-a]pyridine derivatives and their use as positive allosteric modulators of mGluR2 receptors
ES2536433T3 (es) 2010-11-08 2015-05-25 Janssen Pharmaceuticals, Inc. Derivados de 1,2,4-triazolo[4,3-a]piridina y su uso como moduladores alostéricos positivos de receptores mGluR2
US9271967B2 (en) 2010-11-08 2016-03-01 Janssen Pharmaceuticals, Inc. 1,2,4-triazolo[4,3-a]pyridine derivatives and their use as positive allosteric modulators of mGluR2 receptors
US8685404B2 (en) * 2011-01-31 2014-04-01 Oregon Health & Science University Recombinant T-cell receptor ligand for the treatment of cognitive and neuropsychiatric impairment induced by substance addiction
JO3368B1 (ar) 2013-06-04 2019-03-13 Janssen Pharmaceutica Nv مركبات 6، 7- ثاني هيدرو بيرازولو [5،1-a] بيرازين- 4 (5 يد)- اون واستخدامها بصفة منظمات تفارغية سلبية لمستقبلات ميجلور 2
JO3367B1 (ar) 2013-09-06 2019-03-13 Janssen Pharmaceutica Nv مركبات 2،1، 4- ثلاثي زولو [3،4-a] بيريدين واستخدامها بصفة منظمات تفارغية موجبة لمستقبلات ميجلور 2
MX386697B (es) 2014-01-21 2025-03-19 Janssen Pharmaceutica Nv Combinaciones que comprenden agonistas ortostericos o moduladores alostericos positivos del receptor glutamatergico metabotropico de subtipo 2 y su uso
ME03518B (me) 2014-01-21 2020-04-20 Janssen Pharmaceutica Nv Kombinacije koje obuhvataju pozitivne alosterične modulatore ili ortosterične agoniste metabotropnog glutamatergičnog receptora podtipa 2 i njihova primjena
EP3661500B1 (en) 2017-07-31 2026-01-07 Novartis AG Use of mavoglurant in the reduction of cocaine use or in preventing relapse into cocaine use
US20210393621A1 (en) 2018-10-26 2021-12-23 The Research Foundation For The State University Of New York Combination serotonin specific reuptake inhibitor and serotonin 1a receptor partial agonist for reducing l-dopa-induced dyskinesia
IL303248A (en) * 2020-12-11 2023-07-01 Novartis Ag Use of mglur5 antagonists for treating amphetamine addiction
CN114088427A (zh) * 2021-11-22 2022-02-25 昆明理工大学 一种用于惯容器/悬架的性能测试试验台及试验方法

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR0014859A (pt) * 1999-10-15 2002-07-16 Hoffmann La Roche Derivados de benzodiazepina
GB0005700D0 (en) 2000-03-09 2000-05-03 Glaxo Group Ltd Therapy
US6916821B2 (en) * 2001-04-02 2005-07-12 Brown University Methods of treating disorders with Group I mGluR antagonists

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN110151184A (zh) * 2019-04-19 2019-08-23 昆明依利科特科技有限公司 非接触式吸毒人员快速检测系统及方法

Also Published As

Publication number Publication date
CA2498022C (en) 2012-10-23
WO2004024150A2 (en) 2004-03-25
JP2010174039A (ja) 2010-08-12
US8354447B2 (en) 2013-01-15
ATE539768T1 (de) 2012-01-15
AU2003270166A8 (en) 2004-04-30
EP1539149B1 (en) 2012-01-04
ES2381664T3 (es) 2012-05-30
JP2006501265A (ja) 2006-01-12
CA2498022A1 (en) 2004-03-25
AU2003270166A1 (en) 2004-04-30
JP2014074032A (ja) 2014-04-24
US20130210849A1 (en) 2013-08-15
CN102793698A (zh) 2012-11-28
US20060148835A1 (en) 2006-07-06
EP1539149A2 (en) 2005-06-15
BR0314192A (pt) 2005-07-26
WO2004024150A3 (en) 2004-08-19

Similar Documents

Publication Publication Date Title
CN1694701A (zh) 治疗包括成瘾与抑郁症在内的与mGLU受体相关疾病的mGLU受体拮抗剂
Tan et al. Cotinine: pharmacologically active metabolite of nicotine and neural mechanisms for its actions
Branchek et al. Trace amine receptors as targets for novel therapeutics: legend, myth and fact
CN101065014A (zh) 通过诱导逆适应调节神经递质系统的方法
Preti New developments in the pharmacotherapy of cocaine abuse
Hajós et al. The selective norepinephrine reuptake inhibitor antidepressant reboxetine: pharmacological and clinical profile
De Bodinat et al. Agomelatine, the first melatonergic antidepressant: discovery, characterization and development
CN101080224A (zh) 治疗疼痛的方法和组合物
Zomkowski et al. The role of the NMDA receptors and L-arginine–nitric oxide–cyclic guanosine monophosphate pathway in the antidepressant-like effect of duloxetine in the forced swimming test
CN1794981A (zh) 治疗抑郁症和其它情绪障碍的nmda受体拮抗剂和选择性5－羟色胺重摄取抑制剂的组合
CN1784221A (zh) 影响体重减轻的组合物
JP2010510314A (ja) 精神遅滞、ダウン症候群、脆弱ｘ症候群および自閉症の治療方法
CN1555263A (zh) 治疗普通感冒的组合物
Gardoni et al. Safinamide modulates striatal glutamatergic signaling in a rat model of levodopa-induced dyskinesia
Adell Antidepressant properties of substance P antagonists: relationship to monoaminergic mechanisms?
JP2017519827A (ja) ブスピロン代謝産物の使用
JP2020533296A (ja) 薬物誘発性ジスキネジアを治療するためのプリドピジン
WO2008083442A1 (en) Method for formulating combination medications for adhd
Mittur Piribedil: Antiparkinsonian properties and potential clinical utility in dopaminergic disorders
Li et al. A Review of the Recent Advances in the Pharmacological Management of Parkinson's Disease.
Somaini et al. Promising medications for cocaine dependence treatment
Money et al. Treating schizophrenia: novel targets for the cholinergic system
Kim et al. Antiallodynic effect of intrathecal Korean Red Ginseng in cisplatin-induced neuropathic pain rats
Lotfipour et al. The monoamine oxidase (MAO) inhibitor tranylcypromine enhances nicotine self-administration in rats through a mechanism independent of MAO inhibition
Pannu et al. Acetylcholine and depression: Scrutinizing future therapeutic targets for novel drug development

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C12 Rejection of a patent application after its publication
RJ01 Rejection of invention patent application after publication

Application publication date: 20051109